- Home
- BH vs ARCT Comparison
BH vs ARCT Comparison
Compare BH & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BH
- ARCT
- Stock Information
- Founded
- BH 1934
- ARCT 2013
- Country
- BH United States
- ARCT United States
- Employees
- BH N/A
- ARCT N/A
- Industry
- BH Restaurants
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- BH Consumer Discretionary
- ARCT Health Care
- Exchange
- BH Nasdaq
- ARCT Nasdaq
- Market Cap
- BH 606.9M
- ARCT 602.7M
- IPO Year
- BH N/A
- ARCT N/A
- Fundamental
- Price
- BH $169.23
- ARCT $18.69
- Analyst Decision
- BH
- ARCT Strong Buy
- Analyst Count
- BH 0
- ARCT 6
- Target Price
- BH N/A
- ARCT $65.00
- AVG Volume (30 Days)
- BH 1.5K
- ARCT 355.3K
- Earning Date
- BH 11-01-2024
- ARCT 08-05-2024
- Dividend Yield
- BH N/A
- ARCT N/A
- EPS Growth
- BH N/A
- ARCT N/A
- EPS
- BH N/A
- ARCT N/A
- Revenue
- BH $362,194,000.00
- ARCT $163,866,000.00
- Revenue This Year
- BH N/A
- ARCT $13.46
- Revenue Next Year
- BH N/A
- ARCT $5.17
- P/E Ratio
- BH N/A
- ARCT N/A
- Revenue Growth
- BH N/A
- ARCT N/A
- 52 Week Low
- BH $137.01
- ARCT $17.52
- 52 Week High
- BH $219.00
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- BH 37.17
- ARCT 35.80
- Support Level
- BH $174.55
- ARCT $19.95
- Resistance Level
- BH $179.59
- ARCT $21.96
- Average True Range (ATR)
- BH 4.33
- ARCT 1.12
- MACD
- BH -0.45
- ARCT -0.10
- Stochastic Oscillator
- BH 17.68
- ARCT 13.12
About BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations, and Maxim. The majority of revenue is derived from the Restaurant Operations segment. The Restaurant Operations segment includes Steak n Shake and Western Sizzlin Restaurant businesses.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.